Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neuropeptide Y Y5 receptor antagonism causes faster extinction and attenuates reinstatement in cocaine-induced place preference

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of postnatal anoxia on striatal dopamine metabolism and prepulse inhibition in rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical association to FKBP5 rs1360780 in patients with depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DNA methylation regulates CHRNA7 transcription and can be modulated by valproate

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Electro convulsive therapy: Modification of its effect on the autonomic nervous system using anti-cholinergic drugs

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Tesofensine is a triple monoamine reuptake inhibitor which inhibits noradrenaline, 5-HT and dopamine reuptake. Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong and sustained effects in obesity management is not clarified. Tesofensine effectively induces appetite suppression in the diet-induced obese (DIO) rat partially being ascribed to an indirect stimulation of central dopamine receptor function subsequent to blocked dopamine transporter activity. This is interesting, as obese patients have reduced central dopaminergic activity thought to provide a drive for compensatory overeating, but whether treatment with an uptake inhibitor counteracts these changes or not has not been investigated. Tesofensine treatment (2.0mg/kg/day for 14days) caused a pronounced anorexigenic and weight-reducing response in DIO rats as compared to age-matched chow-fed rats. DIO rats also exhibited a marked reduction in baseline extracellular dopamine levels in the nucleus accumbens (NAcc) and prefrontal cortex (PFC), as compared to chow-fed rats using microdialysis. While acute administration of tesofensine (2.0mg/kg) normalized accumbal dopamine levels in DIO rats, the drug had no effect on dopamine levels in chow-fed rats. Tesofensine evoked a stronger stimulatory response on NAcc and PFC dopamine levels in DIO rats, and also induced discrete changes in striatal dopamine D2 receptor expression and transporter binding. In conclusion, tesofensine produces weight loss together with reversal of lowered forebrain dopamine levels in DIO rats, suggesting that tesofensine's anti-obesity effects, at least in part, are associated with positive modulation of central dopaminergic activity.
Original languageEnglish
JournalPharmacology, Biochemistry and Behavior
Volume110C
Pages (from-to)265-271
Number of pages7
ISSN0091-3057
DOIs
Publication statusPublished - 7 Aug 2013

ID: 39915888